Log in to search using one of your social media accounts:

 

Mastectomy patterns, but not rates, are changing in the treatment of early breast cancer. Experience of a single European institution on 2315 consecutive patients.
We report on 15-year trends of mastectomy, mastectomy plus immediate reconstruction and contralateral prophylactic mastectomy (CPM) at an academic institution. METHODS: We identified women diagnosed with unilateral early breast cancer at stage 0-IIa, with tumour size ≤ 4 cm, between 2002 and 2016. Trends were assessed using the Cochrane-Armitage test. Multivariable logistic regression was used to identify factors associated with receipt of mastectomy plus immediate reconstruction. RESULTS: A total of 2315 patients were identified. Of them, 65.7% underwent breast conserving surgery (BCS), while 34.3% unde...
Source: Breast - February 14, 2018 Category: Cancer & Oncology Authors: Fancellu A, Sanna V, Cottu P, Feo CF, Scanu AM, Farina G, Bulla A, Spanu A, Paliogiannis P, Porcu A Tags: Breast Source Type: research

Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials.
CONCLUSION: Among hormone receptor-negative patients, delaying chemotherapy initiation beyond 6 weeks (after surgery) is associated with worse patient outcomes. Moreover, delaying radiotherapy initiation beyond surgery does not compromise outcomes in patients receiving long course adjuvant chemotherapy. PMID: 29432980 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - February 9, 2018 Category: Cancer & Oncology Authors: Abdel-Rahman O Tags: Breast Source Type: research

A quantitative analysis of tumour characteristics in breast cancer patients with extranodal extension in non-sentinel nodes.
This study determined incidence of ENE at NSLN metastasis in patients with a positive SLN biopsy without ENE in 162 symptomatic breast cancer patients who underwent AC between 2009 and 2014 at Cork University Hospital Breast Cancer Service, a teaching hospital of University College Cork. RESULTS: Of 965 sentinel node biopsies performed 251 were identified as SLN positive, 162 (64.5%) underwent further AC. Of the 162 patients, 56.8% (92/162) were positive for ENE at SLN, of these 57.6% (53/92) had NSLN metastasis versus 17.1% (12/70) in the ENE-negative group (χ2 test; P 
Source: Breast - February 3, 2018 Category: Cancer & Oncology Authors: O'Keeffe NA, O'Neill C, Zahere A, Livingstone V, Browne TJ, Redmond HP, Corrigan MA Tags: Breast Source Type: research

Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14-25).
CONCLUSIONS: The TC of breast presents an excellent prognosis, but the contralateral breast cancer tends to be more frequently observed compared to IDC in Korean women. PMID: 29413404 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 30, 2018 Category: Cancer & Oncology Authors: Cho WK, Choi DH, Lee J, Park W, Kim YB, Suh CO, Shin KH, Jeon SH, Kim K, Park KR, Kim JH, Ahn SJ, Yoon WS, Yang DS, Kim J, Lee JH, Yea JW Tags: Breast Source Type: research

Reconstructive surgery and persistent postsurgical pain after mastectomy.
PMID: 29395982 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 30, 2018 Category: Cancer & Oncology Authors: Kendall MC, Castro Alves LJ Tags: Breast Source Type: research

Reply to Kendall and Castro-Alves: Reconstructive surgery and persistent postsurgical pain after mastectomy.
PMID: 29395983 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 30, 2018 Category: Cancer & Oncology Authors: Roth RS, Qi J, Hamill JB, Wilkins EG, Kim HM, Ballard TNS, Pusic AL Tags: Breast Source Type: research

Interval breast cancers in the 'screening with tomosynthesis or standard mammography' (STORM) population-based trial.
CONCLUSION: Interval breast cancer rate amongst screening participants in the STORM trial was marginally lower (and screening sensitivity higher) than estimates amongst 2D-screened women; these findings should be interpreted with caution given the small number of interval cases and the sample size of the trial. Much larger screening studies, or pooled analyses, are required to examine interval cancer rates arising after breast tomosynthesis screening versus digital mammography screening. PMID: 29328943 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 9, 2018 Category: Cancer & Oncology Authors: Houssami N, Bernardi D, Caumo F, Brunelli S, Fantò C, Valentini M, Romanucci G, Gentilini MA, Zorzi M, Macaskill P Tags: Breast Source Type: research

Addressing the paradox of increasing mastectomy rates in an era of de-escalation of therapy: Communication strategies.
Abstract Breast conservation therapy (BCT) was established as the preferred modality of surgical treatment for early stage breast cancer in the early 1990's. Yet, rising mastectomy rates have been observed over the last decade. This increase is a cause for concern as recent large population-based studies have consistently reported improved breast cancer-specific survival and local control rates with BCT, in comparison with mastectomy. There is a pressing need to formulate strategies to effectively inform both patients and practitioners about current data, in the hope of reversing rising mastectomy rates to optimis...
Source: Breast - January 8, 2018 Category: Cancer & Oncology Authors: Tan MP, Silva E Tags: Breast Source Type: research

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.
CONCLUSION: The superiority of fulvestrant 500 mg over fulvestrant 250 mg in patients with LA/MBC in CONFIRM was consistent in both the first- and second-line settings for PFS, and numerically greater in both settings for OS. PMID: 29324303 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 8, 2018 Category: Cancer & Oncology Authors: Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M Tags: Breast Source Type: research

The biology of male breast cancer.
Abstract Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found...
Source: Breast - January 6, 2018 Category: Cancer & Oncology Authors: Fentiman IS Tags: Breast Source Type: research

Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.
CONCLUSION: These results showed that neoadjuvant LET with zoledronic acid could not achieve overall effect for local tumor response. However, patients with a low frequency of γδ T cells would benefit from the treatment including zoledronic acid. (UMIN 000008701). PMID: 29310035 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 5, 2018 Category: Cancer & Oncology Authors: Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M Tags: Breast Source Type: research

Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ.
CONCLUSION: The older age at presentation, high grade of upgrade to invasive cancer, common association with higher grade tumours suggest that PLCIS is an aggressive form of insitu disease. These findings support the view that PLCIS is a more aggressive form of lobular in situ neoplasia and supports the tendency to treat akin to DCIS. PMID: 29310036 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 5, 2018 Category: Cancer & Oncology Authors: Masannat YA, Husain E, Roylance R, Heys SD, Carder PJ, Ali H, Maurice Y, Pinder SE, Sawyer E, Shaaban AM Tags: Breast Source Type: research

A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer.
Abstract AIM: To evaluate the use of the MammaPrint assay, a 70-gene risk signature for early breast cancers, and to correlate genomic risk stratification with individual clinicopathological parameters and clinical risk as assessed by Adjuvant! Online. METHODS: A Dutch Pathology Registry (PALGA)-based cohort study consisting of 1916 patients for which 1946 MammaPrint assay results were synoptically reported from 2013 to 2016. We could retrospectively assess clinical risk for 1146 tumors (58.9%) using Adjuvant! Online (version 8.0 with HER2 status) and for 1155 tumors (59.4%) using PREDICT (version 2.0). ...
Source: Breast - January 5, 2018 Category: Cancer & Oncology Authors: Groenendijk FH, Jager A, Cardoso F, van Deurzen CHM Tags: Breast Source Type: research

Stage-specific incidence and survival of breast cancer in Norway: The implications of changes in coding and classification practice.
Hofvind S Abstract To describe the association between coding and classification practices and observed stage-specific incidence and survival trends in Norway over time. We identified all women diagnosed with invasive breast cancer in the period between 1980 and 2015. Changes in the coding and classification of breast cancer in the study period were described, and stage-specific incidence rates and relative survival were calculated. A total of 90 362 women were diagnosed with primary breast cancer, stage I-IV, or unknown stage, in the study period. Stage-specific incidence was significantly influenced by cha...
Source: Breast - January 4, 2018 Category: Cancer & Oncology Authors: Larsen IK, Myklebust TÅ, Johannesen TB, Møller B, Hofvind S Tags: Breast Source Type: research

Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography.
DISCUSSION: Bilateral interval cancers comprise a small proportion of all interval cancers. Except of a higher proportion of invasive lobular cancers and a more favourable histological grade of invasive cancers, tumour characteristics are comparable for bilateral and unilateral interval breast cancers. PMID: 29306176 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 3, 2018 Category: Cancer & Oncology Authors: van Bommel RMG, Voogd AC, Nederend J, Setz-Pels W, Louwman MWJ, Strobbe LJ, Venderink D, Tjan-Heijnen VCG, Duijm LEM Tags: Breast Source Type: research

Partial breast irradiation: The time is there!
Abstract The conventionally fractionated partial breast irradiation (PBI) IMPORT LOW trial represents the perfect example of how an adequate selection of patients led to a minimal local relapse rate for patients. Coles and colleagues, demonstrated a 5-year non-inferiority local relapse rate for PBI compared to standard whole breast irradiation, together with a significant reduction in terms of breast toxicity using a conventional radiation technique implementable worldwide. Most of enrolled patients had early stage node negative, grade1-2, oestrogen receptor positive, human epidermal growth factor receptor 2 negat...
Source: Breast - December 28, 2017 Category: Cancer & Oncology Authors: Meattini I, Livi L, Pallotta S, Marrazzo L Tags: Breast Source Type: research

Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results.
Abstract OBJECTIVES: Given their inclusion and exclusion criteria, randomized clinical trials (RCT) might not include a population that truly mirrors real life (RL). This raises concerns about the applicability of RCT results in clinical practice. We evaluated the efficacy of anti-HER2 treatment with pertuzumab combined with trastuzumab and a taxane as first-line treatment for HER2-positive metastatic breast cancer in a RL setting, and compared the safety results obtained in our population versus the experimental cohort of the CLEOPATRA RCT, which led to the approval of this therapy. MATERIALS AND METHODS: Pa...
Source: Breast - December 26, 2017 Category: Cancer & Oncology Authors: De Placido S, Giuliano M, Schettini F, Von Arx C, Buono G, Riccardi F, Cianniello D, Caputo R, Puglisi F, Bonotto M, Fabi A, Bilancia D, Ciccarese M, Lorusso V, Michelotti A, Bruzzese D, Veneziani BM, Locci M, De Laurentiis M, Arpino G Tags: Breast Source Type: research

A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.
CONCLUSION: Rare FANCM truncating mutations, other than c.5101C>T and c.5791C>T, may have a role in MBC susceptibility. The inclusion of FANCM in gene panels for research purpose would allow for the identification of a higher number of mutation carriers, thus helping estimate BC risk associated with FANCM mutations. PMID: 29287190 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 26, 2017 Category: Cancer & Oncology Authors: Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L Tags: Breast Source Type: research

Breast cancer in octogenarian. Are we doing our best? A population-registry based study.
Abstract BACKGROUND: The number of old people with breast cancer is estimated to increase during the next years in developed countries. However, management of breast cancer in octogenarians is not well established. The main objective was to evaluate if patients older than 80 years with breast cancer are receiving the most convenient treatment by using a population registry cancer analysis. PATIENTS AND METHODS: A retrospective analysis of a population cancer registry was designed. Data were retrieved from the Castellon Cancer Registry (Valencian Community, Spain). Patient records were analyzed from January 1,...
Source: Breast - December 20, 2017 Category: Cancer & Oncology Authors: Martinez-Ramos D, Simon-Monterde L, Queralt-Martin R, Suelves-Piqueres C, Menor-Duran P, Escrig-Sos J Tags: Breast Source Type: research

Integration of radiation and immunotherapy in breast cancer - Treatment implications.
Abstract Radiation therapy (RT) has been successfully used in the treatment of breast cancer (BC) for over a century. While historically thought to be immunosuppressive, new data have shown that RT can work together with the immune system to eliminate cancer. It can cause immunogenic cell death and facilitate tumor neoantigen presentation and cross-priming of tumor-specific T-lymphocytes, turning irradiated tumor into an in-situ vaccine. Unfortunately, due to various immune escape mechanism put in place by the tumor, RT alone rarely results in a systemic response of metastatic disease sites (known as the abscopal ...
Source: Breast - December 15, 2017 Category: Cancer & Oncology Authors: Ye JC, Formenti SC Tags: Breast Source Type: research

Development and psychometric validation of a shorter version of the Breast Cancer Treatment Outcome Scale (BCTOS-12).
CONCLUSION: The modified BCTOS questionnaire with only 12 items (BCTOS-12) is shorter, easier to interpret, and shows good validity. PMID: 29248875 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 14, 2017 Category: Cancer & Oncology Authors: Hennigs A, Heil J, Wagner A, Rath M, Moosbrugger H, Kelava A, Golatta M, Hug S, Riedel F, Rauch G, Feißt M Tags: Breast Source Type: research

Associations between adjuvant radiotherapy and different causes of death in a German breast cancer cohort.
CONCLUSION: In line with recent studies, 3D-conformal RT did not significantly increase mortality from non-BC causes in the German MARIEplus cohort. Since long-term data are still sparse and event rates low in BC-cohorts, who received modern RT, investigation of possible late RT effects on mortality beyond 14 years of follow-up is warranted. PMID: 29248876 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 14, 2017 Category: Cancer & Oncology Authors: Obi N, Eulenburg C, Seibold P, Eilber U, Thöne K, Behrens S, Chang-Claude J, Flesch-Janys D Tags: Breast Source Type: research

Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia.
CONCLUSION: In several high-income countries, the fall in breast cancer mortality, due to improved treatment and diagnosis, has been the major success in the management of any common cancer over the last three decades. There are, however, persistent disparities in the global decline in breast cancer, which call for urgent management improvements in several areas of the world, particularly in middle-income countries. PMID: 29246526 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 12, 2017 Category: Cancer & Oncology Authors: Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C Tags: Breast Source Type: research

A retrospective review of phyllodes tumours of the breast: A single institution experience.
CONCLUSION: The presence of tumour necrosis is a significant negative prognostic factor. Breast-conserving surgery may be adequate in providing local control, given negative surgical margins. PMID: 29232600 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 9, 2017 Category: Cancer & Oncology Authors: Ganesh V, Drost L, Lee J, Wan BA, Zhang L, Rakovitch E, Vesprini D, Slodkowska E, Zeng KL, Sousa P, Yee C, Lam H, Chow E Tags: Breast Source Type: research

Meta-analysis of flap perfusion and donor site complications for breast reconstruction using pedicled versus free TRAM and DIEP flaps.
CONCLUSION: Although pTRAM flaps are being replaced by fTRAM and DIEP flaps, which exhibit fewer complications related to flap ischemia and donor site morbidity, it was unclear from the literature which flap type was most beneficial regarding flap vascularity and donor site morbidity. Hence, surgeons should choose the appropriate option based on their preferences and on patient factors.. PMID: 29227815 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 8, 2017 Category: Cancer & Oncology Authors: Jeong W, Lee S, Kim J Tags: Breast Source Type: research

Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.
Abstract BACKGROUND: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown. MATERIAL AND METHODS: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: 16 weeks. RESULTS: A total of 581 patients were included; 74% had clinical stage III. Forty-three patients st...
Source: Breast - December 6, 2017 Category: Cancer & Oncology Authors: Silva SB, Pereira AAL, Marta GN, de Barros Lima KML, de Freitas TB, Matutino ARB, de Azevedo Souza MCL, de Azevedo RGMV, de Viveiros PAH, da Silva Lima JM, Filassi JR, de Andrade Carvalho H, Piato JRM, Mano MS Tags: Breast Source Type: research

Genetic alterations in sporadic triple negative breast cancer.
CONCLUSION: We show a strong association between TNBC and mutations in BRCA1/2 genes and the poor outcome of these patients. Moreover, we identified several other unknown mutations putatively associated with the poor prognosis of TNBC tumors. We also discovered novel mutations never before associated with breast cancer that could putatively account for the poor prognosis of the TNBC tumors. PMID: 29202330 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 1, 2017 Category: Cancer & Oncology Authors: Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I Tags: Breast Source Type: research

Moderate intermittent negative pressure increases invasiveness of MDA-MB-231 triple negative breast cancer cells.
Abstract BACKGROUND: To investigate the effect moderate intermittent negative pressure breast reconstructive model exerts on human triple negative breast cancer cell (TNBC) invasion and explore the related mechanism. METHODS: The human TNBC cell line MDA-MB-231 was used. Cells in external volume expansion (EVE) group were exposed to an intermittent -25 mmHg for 12 h; the pressure for non-EVE group was constantly 0 mmHg. In vivo, MDA-MB-231 cell suspensions were injected subcutaneously into dorsal skin of nude mice (n = 27 mice/group). Tumors on mice in EVE group receive...
Source: Breast - November 25, 2017 Category: Cancer & Oncology Authors: Liu W, Fu X, Yang Z, Li S, Cao Y, Li Q, Luan J Tags: Breast Source Type: research

Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype.
CONCLUSIONS: Loss of HR and P53 expression in HR-positive mammospheres evidences the minor population of CSC which shares characteristics with the TNBC phenotype. PMID: 29182983 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 25, 2017 Category: Cancer & Oncology Authors: Laranjo M, Carvalho MJ, Costa T, Alves A, Oliveira RC, Casalta-Lopes J, Cordeiro P, Botas F, Abrantes AM, Paiva A, Oliveira C, Botelho MF Tags: Breast Source Type: research

Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).
CONCLUSIONS: OS, duration of trastuzumab, and frequency of cardiac monitoring increased over the study period. Outcomes for trastuzumab in this heterogeneous real world population were reassuringly comparable to those from clinical trials, with the median OS > 3 years in Group Two and 25% of patients living 7 years or longer. PMID: 29172171 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 21, 2017 Category: Cancer & Oncology Authors: Daniels B, Kiely BE, Lord SJ, Houssami N, Lu CY, Ward RL, Pearson SA Tags: Breast Source Type: research

Psychosocial interventions in breast cancer survivorship care.
Abstract Cancer distress screening and subsequent referral for psychosocial intervention has been mandated for continued cancer center accreditation. Increasing emphasis is being placed on the referral component of this mandate, ensuring that patient distress is not only identified but also effectively treated. Many evidence-based interventions exist for cancer distress. Specific interventions can effectively target biopsychosocial impacts of stress and promote adaptive coping, focusing on problem-solving, social support utilization, assertive communication, sexual health and intimacy, adherence to medical and sup...
Source: Breast - November 20, 2017 Category: Cancer & Oncology Authors: Gudenkauf LM, Ehlers SL Tags: Breast Source Type: research

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Abstract BACKGROUND: Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). METHODS: This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was coll...
Source: Breast - November 18, 2017 Category: Cancer & Oncology Authors: Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, Montemurro F, Bernardo A, Risi E, Zanardi E, Ziliani S, Mura S, Dellepiane C, Del Mastro L, Minisini AM, Puglisi F Tags: Breast Source Type: research

Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues.
Abstract To allow women at high genetic risk of breast cancer to benefit from prevention or early prevention strategies, a screening programme is required to identify them. The present review considers the likelihood of key outcomes that would arise from such a programme, in relation to behavioural, emotional and informed choice outcomes. The likelihood of outcomes in each category is considered in relation to the limited direct evidence and relevant indirect evidence, given the dearth of studies that have directly studied the effects of communication of personal genetic risk of breast cancer. Overall, there is pr...
Source: Breast - November 18, 2017 Category: Cancer & Oncology Authors: French DP, Howell A, Evans DG Tags: Breast Source Type: research

Targeting FGFR pathway in breast cancer.
This article summarizes the main molecular alterations of FGFRs, as well as the available preclinical and clinical data with FGFR inhibitors in breast cancer, and discusses new opportunities for the clinical development of these agents in patients with breast cancer. PMID: 29156384 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 17, 2017 Category: Cancer & Oncology Authors: Perez-Garcia J, Muñoz-Couselo E, Soberino J, Racca F, Cortes J Tags: Breast Source Type: research

Interaction with the GDF8/11 pathway reveals treatment options for adenocarcinoma of the breast.
In this study, we investigated the interaction of breast adenocarcinoma with the ubiquitously present protein Follistatin and subsequently the GDF8/11 pathway. We analyzed primary histological samples from adenocarcinoma patients for expression of Follistatin and GDF8/11. Furthermore, expression levels of Follistatin and GDF8/11 in MCF7 were compared with MCF10a cells. From the resulting data, GDF8 and Follistatin were used as chemotherapeutic agents in MCF7 cells and their migratory, proliferative behavior and viability were measured. From the experiments, we were able to detect a significantly increased expression of Fol...
Source: Breast - November 17, 2017 Category: Cancer & Oncology Authors: Wallner C, Drysch M, Becerikli M, Jaurich H, Wagner JM, Dittfeld S, Nagler J, Harati K, Dadras M, Philippou S, Lehnhardt M, Behr B Tags: Breast Source Type: research

Is chronic postsurgical pain surgery-induced? A study of persistent postoperative pain following breast reconstruction.
CONCLUSIONS: The substantial rate of preoperative pain and comparable prevalence of preoperative and postoperative pain ratings suggest that persistent pain after breast reconstruction may not necessarily reflect surgery-induced pain. Future research will need to determine those factors that contribute to long-term pain following breast reconstruction. PMID: 29145033 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 13, 2017 Category: Cancer & Oncology Authors: Roth RS, Qi J, Hamill JB, Kim HM, Ballard TNS, Pusic AL, Wilkins EG Tags: Breast Source Type: research

The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy.
CONCLUSION: Benefits of hypnosis sedation on breast cancer treatment are very encouraging and further promote the concept of integrative oncology. PMID: 29136523 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 11, 2017 Category: Cancer & Oncology Authors: Berlière M, Roelants F, Watremez C, Docquier MA, Piette N, Lamerant S, Megevand V, Van Maanen A, Piette P, Gerday A, Duhoux FP Tags: Breast Source Type: research

Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
In this study we characterize the adoption of AIs in Portugal, variables associated with treatment administration, and compare its effectiveness (either in monotherapy or sequential therapy) to tamoxifen monotherapy (TAM). PATIENTS AND METHODS: This was a retrospective cohort study that included postmenopausal women with stage I-III hormone receptor (HR) positive BC diagnosed from 2006 to 2008 and treated with adjuvant endocrine therapy in four participating institutions. RESULTS: Of the 1283 eligible patients, 527 (41%) received an AI (16% as monotherapy, 25% as sequential therapy) and 756 (59%) TAM. Patients tr...
Source: Breast - November 10, 2017 Category: Cancer & Oncology Authors: Ferreira AR, Palha A, Correia L, Filipe P, Rodrigues V, Miranda A, André R, Fernandes J, Gouveia J, Passos-Coelho JL, Moreira A, Brito M, Ribeiro J, Metzger-Filho O, Lin NU, Costa L, Vaz-Luis I Tags: Breast Source Type: research

Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
CONCLUSIONS: Oncotype DX was the only gene expression test that was estimated to reduce costs versus standard care in Germany. The reimbursement of Oncotype DX testing in standard clinical practice in Germany should be considered. PMID: 29128582 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 9, 2017 Category: Cancer & Oncology Authors: Lux MP, Nabieva N, Hildebrandt T, Rebscher H, Kümmel S, Blohmer JU, Schrauder MG Tags: Breast Source Type: research

Patients' experiences with decisions on timing of chemotherapy for breast cancer.
CONCLUSION: The need to make a treatment decision on NAC was found to be made explicit in only a small number of adjuvant treated patients, in particular in BC stage II. Less than half of the respondents felt they had a real choice. PMID: 29128583 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 9, 2017 Category: Cancer & Oncology Authors: de Ligt KM, Spronk PER, van Bommel ACM, Vrancken Peeters MTFD, Siesling S, Smorenburg CH, Nabon Breast Cancer Audit group Tags: Breast Source Type: research

Editorial: Approaches of the treatment of DCIS.
PMID: 29117902 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 5, 2017 Category: Cancer & Oncology Authors: Narod SA Tags: Breast Source Type: research

Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study.
Abstract BACKGROUND: Previous studies suggest that immediate reconstruction following mastectomy produces superior results over delayed procedures. However, for medical or oncological reasons, some patients may be poor candidates for immediate reconstruction. We compared complications and patient-reported outcomes between immediate and delayed breast reconstructions in a prospective, multicenter study. METHODS: 1957 patients (1806 immediate, 151 delayed) met eligibility criteria. Demographic data, major complications, infections, and reconstructive failure rates were evaluated. Patient-reported outcomes were ...
Source: Breast - November 2, 2017 Category: Cancer & Oncology Authors: Yoon AP, Qi J, Brown DL, Kim HM, Hamill JB, Erdmann-Sager J, Pusic AL, Wilkins EG Tags: Breast Source Type: research

Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience.
CONCLUSION: The current study showed an improvement in the prognosis of breast cancer patients over the past 30 years and pointed to the importance of evaluating covariates with time-varying effects. PMID: 29102782 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 2, 2017 Category: Cancer & Oncology Authors: Houzé de l'Aulnoit A, Rogoz B, Pinçon C, Houzé de l'Aulnoit D Tags: Breast Source Type: research

Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy  ± trastuzumab.
CONCLUSIONS: Prophylactic ACE inhibitor does not attenuate development of LV dysfunction or heart failure in patients receiving anthracycline chemotherapy ± trastuzumab. Beta-blocker attenuated reduction in LVEF and new heart failure diagnosis. However, the effect in patients only receiving anthracycline is less certain. Studies examining the effect on mortality are required. PMID: 29101824 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 1, 2017 Category: Cancer & Oncology Authors: Gujral DM, Lloyd G, Bhattacharyya S Tags: Breast Source Type: research

Radiation therapy after breast conserving surgery increases long-term breast conservation for DCIS patients.
PMID: 29100639 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - October 31, 2017 Category: Cancer & Oncology Authors: Kaidar-Person O, Meattini I, Poortmans P Tags: Breast Source Type: research

A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer.
Abstract This viewpoint is a personal reflection on the values and merits of immunohistochemistry in current breast cancer diagnosis. Immunohistochemistry is a validated mainstay in molecular subtyping of invasive breast cancer. Immunohistochemical assessment of hormone receptor status and HER2 expression is used to determine the clinico-pathological surrogate of breast cancer intrinsic subtypes, which guide neoadjuvant and adjuvant therapy. The advent of genomic prognostic signatures and qualitative mRNA-based assays makes some clinicians and researchers wonder whether immunohistochemistry should be abandoned. Ho...
Source: Breast - October 31, 2017 Category: Cancer & Oncology Authors: Van Bockstal M, Floris G, Galant C, Lambein K, Libbrecht L Tags: Breast Source Type: research

Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.
CONCLUSIONS: The prognostic stage provided accurate prognostic information for LABC compared with anatomic TNM stage. It will lead to accuracy in prognosis prediction and optimal treatment selection, and therefore, better outcomes. PMID: 29100045 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - October 31, 2017 Category: Cancer & Oncology Authors: Wang M, Chen H, Wu K, Ding A, Zhang M, Zhang P Tags: Breast Source Type: research

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
CONCLUSIONS: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities. PMID: 29100043 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - October 26, 2017 Category: Cancer & Oncology Authors: Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhard Tags: Breast Source Type: research

Therapeutic approaches for protecting bone health in patients with breast cancer.
GG Abstract Improvements in the survival of patients with breast cancer, together with a better understanding of the pathology of the disease, have led to the emergence of bone health as a key aspect of patient management. Patients with breast cancer are typically at risk of skeletal complications throughout their disease course. The receptor activator of nuclear factor κ B ligand (RANKL) inhibitor denosumab and bisphosphonates (e.g. zoledronic acid) are approved in Europe for the prevention of skeletal-related events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) in adults...
Source: Breast - October 23, 2017 Category: Cancer & Oncology Authors: Lüftner D, Niepel D, Steger GG Tags: Breast Source Type: research

External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.
This study was designed to validate Modified Breast-GPA. PATIENTS AND METHODS: Clinical data of 668 BC patients diagnosed with BM at four institutions between 1996 and 2016 were reviewed. Patients were classified by Breast-GPA and Modified Breast-GPA. Overall survival (OS) was calculated from time of BM diagnosis to death or last follow-up. Cox proportional models were used to calculate hazard-ratios and their 95% CI. The performances of Breast-GPA and Modified Breast-GPA were compared using Harrell's concordance index. RESULTS: Median age at BM diagnosis was 56 years (range 24-85). At last follow-up, 632 patient...
Source: Breast - October 23, 2017 Category: Cancer & Oncology Authors: Griguolo G, Jacot W, Kantelhardt E, Dieci MV, Bourgier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A Tags: Breast Source Type: research